ライフサイエンスコーパス: dapagliflozin

1 arxiga or any combination therapy containing dapagliflozin.

2 en after displacement of kidney binding with dapagliflozin.

3 patients in the dapagliflozin 5 mg (n=277), dapagliflozin 10 mg (n=296), and placebo (n=260) groups,

4 fety analyses (dapagliflozin 5 mg [n=277] vs dapagliflozin 10 mg [n=296] vs placebo [n=260]; 778 of t

5 e dapagliflozin 5 mg group, five (2%) in the dapagliflozin 10 mg group, and three (1%) in the placebo

6 and -0.84% (-0.98 to -0.70, p<0.0001) in the dapagliflozin 10 mg group.

7 stem, we randomly assigned (1:1) patients to dapagliflozin 10 mg once a day or to placebo, with rando

8 mg by subcutaneous injection plus once-daily dapagliflozin 10 mg oral tablets, exenatide with dapagli

9 Dapagliflozin 10 mg significantly improved blood pressur

10 2% [95% CI -0.56 to -0.28; p<0.0001] and for dapagliflozin 10 mg vs placebo was -0.45% [-0.58 to -0.3

11 07 (80%) patients in the dapagliflozin 5 mg, dapagliflozin 10 mg, and placebo groups, respectively; s

12 in 2.5 mg, n=135; dapagliflozin 5 mg, n=133; dapagliflozin 10 mg, n=132; placebo, n=134).

13 ith -0.67% (-0.81 to -0.53, p=0.0002) in the dapagliflozin 2.5 mg group, -0.70% (-0.85 to -0.56, p<0.

14 ncluded in analysis of the primary endpoint (dapagliflozin 2.5 mg, n=135; dapagliflozin 5 mg, n=133;

15 ed in similar proportions of patients in the dapagliflozin (2-4%) and placebo groups (3%).

16 ly assigned to receive one of three doses of dapagliflozin (2.5 mg, n=137; 5 mg, n=137; or 10 mg, n=1

17 2 to -5.51]; placebo-adjusted difference for dapagliflozin -4.28 mm Hg [-6.54 to -2.02]; p=0.0002).

18 Among patients in the dapagliflozin 5 mg (n=277), dapagliflozin 10 mg (n=296),

19 ment groups and included in safety analyses (dapagliflozin 5 mg [n=277] vs dapagliflozin 10 mg [n=296

20 up, -0.70% (-0.85 to -0.56, p<0.0001) in the dapagliflozin 5 mg group, and -0.84% (-0.98 to -0.70, p<

21 idosis occurred in four (1%) patients in the dapagliflozin 5 mg group, five (2%) in the dapagliflozin

22 sing an interactive voice response system to dapagliflozin 5 mg or 10 mg once daily, given orally, or

23 mean difference from baseline to week 24 for dapagliflozin 5 mg vs placebo was -0.42% [95% CI -0.56 t

24 %), 235 (79%), and 207 (80%) patients in the dapagliflozin 5 mg, dapagliflozin 10 mg, and placebo gro

25 imary endpoint (dapagliflozin 2.5 mg, n=135; dapagliflozin 5 mg, n=133; dapagliflozin 10 mg, n=132; p

26 Dapagliflozin, a selective inhibitor of sodium-glucose c

27 Dapagliflozin, a selective sodium-glucose cotransporter-

28 In vivo, dapagliflozin acutely induced renal glucose excretion in

29 ignificantly greater in patients assigned to dapagliflozin (adjusted mean change from baseline -0.63%

30 gnificantly reduced in the group assigned to dapagliflozin (adjusted mean change from baseline -11.90

31 ne (-0.4% [95% CI -0.6 to -0.1]; p=0.004) or dapagliflozin alone (-0.6% [-0.8 to -0.3]; p<0.001).

32 , exenatide alone (n=231; n=1 untreated), or dapagliflozin alone (n=233).

33 T2 inhibitor dapagliflozin with exenatide or dapagliflozin alone in patients with type 2 diabetes ina

34 , 2012, we randomly assigned 225 patients to dapagliflozin and 224 to placebo.

35 ody weight decreased by 0.92 to 1.61 kg with dapagliflozin and increased by 0.43 kg with placebo (mea

36 nsulin dose decreased by 0.63 to 1.95 U with dapagliflozin and increased by 5.65 U with placebo (mean

37 Adverse events were similar in the dapagliflozin and placebo groups (98 [44%] patients vs 9

38 um-glucose cotransporter 2 (SGLT2) inhibitor dapagliflozin and the insulin sensitizer pioglitazone.

39 (SGLT2) inhibitors, including empagliflozin, dapagliflozin, and canagliflozin, are now widely approve

40 Canagliflozin, dapagliflozin, and empagliflozin accounted for 53%, 42%,

41 Canagliflozin, dapagliflozin, and empagliflozin, all recently approved

42 We have identified dapagliflozin as a potent and selective inhibitor of the

43 e aimed to assess the efficacy and safety of dapagliflozin as an add-on to adjustable insulin in pati

44 zin (25-600 ng mL(-1)) in human plasma using dapagliflozin as an internal standard (IS).

45 ng specificities for these transporters (eg, dapagliflozin, canagliflozin, and empagliflozin) can slo

46 T2, and SGLT2-specific inhibitors, including dapagliflozin, canagliflozin, and empagliflozin, increas

47 lobin A(1c) decreased by 0.79% to 0.96% with dapagliflozin compared with 0.39% with placebo (mean dif

48 of bladder and breast cancer was noted with dapagliflozin compared with control.

49 Dapagliflozin could benefit patients with type 2 diabete

50 a sodium-glucose cotransporter 2 inhibitor (dapagliflozin), depleting neutrophils or Kupffer cells,

51 zin), but not to any significant extent with dapagliflozin, empagliflozin, or phlorizin.

52 ron emission tomography with 4-[(18)F]fluoro-dapagliflozin (F-Dapa).

53 Dapagliflozin (Farxiga), alone, or in the fixed dose com

54 rofile, have prompted clinical evaluation of dapagliflozin for the treatment of type 2 diabetes.

55 lumn life span and achieve the separation of dapagliflozin from potential interferences, especially i

56 (95% CI -2.1 to -1.8) in the exenatide plus dapagliflozin group, -1.6% (-1.8 to -1.4) in the exenati

57 (57%) of 231 patients in the exenatide plus dapagliflozin group, 124 (54%) of 230 patients in the ex

58 group, and 121 (52%) of 233 patients in the dapagliflozin group.

59 atide group, and -1.4% (-1.6 to -1.2) in the dapagliflozin group.

60 genital infections were more frequent in the dapagliflozin groups (2.5 mg, 11 patients [8%]; 5 mg, 18

61 serious adverse events (four in each of the dapagliflozin groups and five in the placebo group).

62 th the placebo group, patients in the pooled dapagliflozin groups had a higher rate of hypoglycemic e

63 These data suggest that dapagliflozin has the potential to be an efficacious tre

64 Co-initiation of exenatide and dapagliflozin improved various glycaemic measures and ca

65 Dapagliflozin improves glycemic control, stabilizes insu

66 ectrometry (LC-MS/MS) bioanalytical assay of dapagliflozin in human plasma.

67 We assessed the efficacy and safety of dapagliflozin in patients who have inadequate glycaemic

68 h the sodium glucose transporter 2 inhibitor dapagliflozin induced production of GLP1 and IL6.

69 INTERPRETATION: Our results suggest that dapagliflozin is a promising adjunct treatment to insuli

70 Dapagliflozin is a sodium-glucose cotransporter-2 inhibi

71 r empagliflozin and m/z 407.00 to 328.81 for dapagliflozin (IS) was employed utilizing negative mode

72 gliflozin 10 mg oral tablets, exenatide with dapagliflozin-matched oral placebo, or dapagliflozin wit

73 abetic men were randomized to receive either dapagliflozin (n = 12) or placebo (n = 6) for 2 weeks.

74 igned 695 patients to receive exenatide plus dapagliflozin (n=231), exenatide alone (n=231; n=1 untre

75 me to receive placebo or 2.5, 5, or 10 mg of dapagliflozin, once daily, for 48 weeks.

76 Dapagliflozin potently and selectively inhibited human S

77 ng glucose analog uptake were used to assess dapagliflozin's ability to inhibit sodium-dependent and

78 The assay also quantifies dapagliflozin's major systemic circulating glucuronide m

79 At week 24, both doses of dapagliflozin significantly reduced HbA1c compared with

80 Exenatide plus dapagliflozin significantly reduced HbA1c from baseline

81 GlcNAcylated protein levels in SKO mice, and dapagliflozin successfully prevented the development of

82 rats were performed to assess the ability of dapagliflozin to improve fed and fasting plasma glucose

83 study was performed to assess the ability of dapagliflozin to improve glucose utilization after multi

84 Addition of dapagliflozin to metformin provides a new therapeutic op

85 correctly and non-randomly allocated to only dapagliflozin treatment groups were included in the safe

86 Dapagliflozin treatment induced glucosuria and markedly

87 Once-daily dapagliflozin treatment over 2 weeks significantly lower

88 Surprisingly, following dapagliflozin treatment, EGP increased substantially and

89 reased by approximately 18% after 2 weeks of dapagliflozin treatment, while placebo-treated subjects

90 Exenatide plus dapagliflozin was significantly superior to either drug

91 The C-aryl glucoside 6 (dapagliflozin) was identified as a potent and selective

92 or agonist exenatide and the SGLT2 inhibitor dapagliflozin with exenatide or dapagliflozin alone in p

93 with dapagliflozin-matched oral placebo, or dapagliflozin with exenatide-matched placebo injections.

94 and glycaemic effects of the SGLT2 inhibitor dapagliflozin with placebo in patients with inadequately

95 SGLT2 inhibitor exposure time was for use of dapagliflozin, with 5% for empagliflozin, and 1% for can